ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors
January 30, 2012 12:00 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Jan. 30, 2012 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody expertise, today announced...
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
January 27, 2012 06:30 ET
|
ImmunoGen, Inc.
Product pipeline progress includes continued advancement of trastuzumab emtansine (T-DM1) toward Phase III data reporting and marketing submission in 2012, initiation of SAR3419 multi-study Phase...
ImmunoGen, Inc. Announces Webcast of Presentation at the J.P. Morgan 30th Annual Healthcare Conference
January 03, 2012 14:00 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Jan. 3, 2012 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation...
ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly
December 20, 2011 06:30 ET
|
ImmunoGen, Inc.
Agreement provides Lilly, a leader in the development of important cancer therapeutics, with access to ImmunoGen's TAP technology
ImmunoGen to receive $20 million upfront, milestone payments...
ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 22nd Annual Healthcare Conference
December 06, 2011 06:30 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Dec. 6, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation...
ImmunoGen, Inc. Earns Milestone Payment From Amgen With IND Achievement for Second TAP Compound
November 14, 2011 06:30 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Nov. 14, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
ImmunoGen, Inc. Named One of The Boston Globe's 2011 Top Places to Work
November 07, 2011 07:30 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Nov. 7, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that it has been...
ImmunoGen, Inc. Earns Milestone From Amgen With IND Achievement
November 03, 2011 06:30 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Nov. 3, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
November 02, 2011 13:57 ET
|
ImmunoGen, Inc.
WALTHAM, Mass., Nov. 2, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Company...
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
October 27, 2011 16:01 ET
|
ImmunoGen, Inc.
Lead product candidates have notable developments, while pipeline continues to expand.
Recent progress includes positive trastuzumab emtansine (T-DM1) clinical data, advancement of SAR3419...